Cellectar Biosciences reports 79.2% major response rate in Phase 2 CLOVER-WaM iopofosine I 131

Cellectar said Phase 2 CLOVER-WaM subset results for iopofosine I 131 in BTK inhibitor-refractory Waldenström macroglobulinemia showed a 79.2% major response rate, with plans for a Phase 3 trial in early 2027 and a targeted U.S. accelerated-approval filing in 1H27.